Journal of Cystic Fibrosis
Volume 2, Issue 1 , Pages 25-28 , March 2003

A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis

  • S.P. Conway

      Affiliations

    • Regional Adult CF Unit, Seacroft Hospital, York Road, Leeds, UK
    • Corresponding Author InformationCorresponding author
    • ,
  • C. Etherington

      Affiliations

    • Regional Adult CF Unit, Seacroft Hospital, York Road, Leeds, UK
    • ,
  • D.G. Peckham

      Affiliations

    • Regional Adult CF Unit, Seacroft Hospital, York Road, Leeds, UK
    • ,
  • A. Whitehead

      Affiliations

    • Pharmacy Department, Seacroft Hospital, York Road, Leeds, UK

References 

  1. Chanarin N, Johnston SL. Leukotrienes as a targeted asthma therapy. Drugs. 1994;47:12–24
  2. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicentre study. Clin Ther. 1997;19:675–690
  3. Nathan RA, Bernstein JA, Bielory L, Bonuccelli CM, Calhoun WT, Galant SP, et al. Zafirulast improves asthma symptoms and quality of life in patients with moderate reversible air flow obstruction. J Allergy Clin Immunol. 1998;102:935–942
  4. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and aetiology. Pediatr Pulmonol. 1997;24:137–142
  5. Berger M, Konstan MW. Immunopathogenesis of cystic fibrosis lung disease. In: Yankaskas JR, Knowles MR, editors. Cystic Fibrosis in Adults. Lippincott-Raven, 1999. p. 115–43
  6. Sampson AP, Spencer DA, Green CP, Piper PJ, Price JF. Leukotrienes in the sputum and urine of cystic fibrosis children. Br J Clin Pharmacol. 1990;30:861–869
  7. Spencer DA, Sampson AP, Green CP, Costello JF, Piper PJ, Price JF. Sputum cysteinyl–leukotriene levels correlate with the severity of pulmonary disease in children with cystic fibrosis. Pediatr Pulmonol. 1992;12:90–94
  8. Greally P, Hussein MJ, Cook AJ, Samson AP, Piper PJ, Price JF. Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child. 1993;68:389–392
  9. Morice AH, Kastelik JA, Aziz I. Montelukast sodium in cystic fibrosis. Thorax. 2001;56:244
  10. Schmitt-Grohe S, Eickmeier O, Bez C, Schubert R, Steffan J, Zielen S. Randomised controlled trial of montelukast (Singulair) in cystic fibrosis. J Cystic Fibrosis (2001), Abstracts of 24th European Cystic Fibrosis Conference, Vienna, poster 167
  11. Ranasinha C, Assoufi B, Shak S, et al.  Efficacy and safety of short-term administration of aerosolised recombinant human DNase1 in adults with stable stage cystic fibrosis. Lancet. 1993;342:199–202
  12. Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnoea. Rehab Nurs. 1989;14:323–325
  13. Taussig LM, Kattwinkel J, Friedewald WT, di Sant Agnase PA. A new prognostic score and clinical evaluation system for cystic fibrosis. J Pediatr. 1973;82:380–390
  14. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979;8:7–20
  15. Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet. 1993;342:465–469
  16. Konstan MW, Walenga RW, Hilliard KA, Hilliard JB. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis. 1993;148:896–901

PII: S1569-1993(02)00142-X

doi: 10.1016/S1569-1993(02)00142-X

Journal of Cystic Fibrosis
Volume 2, Issue 1 , Pages 25-28 , March 2003

Article Tools

* Image Usage & Resolution